Handel nachbörslich: 1.79 -0.01 -0.56%

MAIA Biotechnology Inc (MAIA)

Überblick Nachrichten Preisverlauf Forum Prognose

MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten

MAIA Biotechnology Inc (MAIA)

MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten

MAIA Biotechnology Reports Positive Phase 2 Trial Results - TipRanks

Why Is MAIA Biotechnology Stock Trading Higher On Thursday?MAIA Biotechnology (AMEX:MAIA) - Benzinga

MAIA Biotechnology's Promising Results in Lung Cancer Trial | MA - GuruFocus

MAIA Biotechnology Says New Responder In Non-Small Cell Lung Cancer Phase 2 Clinical Trial - marketscreener.com

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial - Business Wire

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer - BioSpace

MAIA Biotechnology Reports Promising Results from THIO-101 Phase 2 Trial | MAIA Stock News - GuruFocus

Maia Biotechnology Says Ateganosine Treatment Extends Median Overall Survival in Lung Cancer Study - marketscreener.com

Maia Biotechnology stock rises following positive trial results By Investing.com - Investing.com Canada

Maia Biotechnology stock rises following positive trial results - Investing.com Australia

MAIA Biotechnology Showcases Promising THIO-101 Trial Data - TipRanks

MAIA Biotechnology Announces Private Placement Agreement - TipRanks

MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading 4.1% Higher – Still a Buy? - Defense World

MAIA Biotechnology secures $669,500 in private placement By Investing.com - Investing.com South Africa

MAIA Biotechnology Announces Private Placement of Approximately $669,500 - BioSpace

MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial - Yahoo

CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 - BioSpace

MAIA Biotechnology secures $669,500 in private placement - Investing.com

MAIA Biotechnology doubles authorized shares - Investing.com Australia

MAIA Biotechnology doubles authorized shares By Investing.com - Investing.com South Africa

MAIA Biotechnology Increases Authorized Common Stock Shares - TipRanks

MAIA Biotechnology Approves Key Changes at Annual Meeting - TipRanks

MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - Business Wire

MAIA Biotechnology Announces Director Participation in Recent Private Placement - Business Wire

Best Momentum Stocks to Buy for May 6th - The Globe and Mail

MAIA Biotechnology Raises $1.08M in Private Placement - TipRanks

MAIA Biotechnology launches $1.08M private placement - MSN

CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire

MAIA Biotechnology secures $1.08 million in private placement By Investing.com - Investing.com Canada

Maia Biotechnology Announces $1.08 Million Private Placement - marketscreener.com

MAIA Biotechnology secures $1.08 million in private placement - Investing.com

MAIA Biotechnology Raises $1.08M at $1.50 Per Share to Advance Phase II Cancer Trial - Stock Titan

MAIA Biotechnology Announces $1.08 Million Private Placement - Business Wire

MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - Stock Titan

MAIA Biotechnology Inc (MAIA) Stock: A 52-Week Tale of Drops and Gains - investchronicle.com

Do investors need to be concerned about MAIA Biotechnology Inc (MAIA)? - uspostnews.com

MAIA Biotechnology Inc: Navigating Market Fluctuations with a 60.66M Market Cap - investchronicle.com

MAIA Biotechnology Inc [MAIA] stock for 50,000 USD was acquired by Guerrero Ramiro - knoxdaily.com

MAIA’s Q2 earnings predictions: What the experts say - uspostnews.com

MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 14.8% – Here’s Why - Defense World

MAIA Biotechnology publishes preclinical data for telomere-targeting THIO dimer - MSN

MAIA stock touches 52-week low at $1.41 amid market challenges - Investing.com India

MAIA Biotechnology- Phase 2 Trial Thio-101 Expansion Underway Potential Filing In 2026 For Accelerated Approval - MarketScreener

MAIA Biotechnology targets 2026 for FDA approval of cancer drug - Investing.com

Breakthrough Cancer Drug Pipeline: MAIA's Telomere-Targeting Therapy Eyes FDA Fast Track - Stock Titan

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - Business Wire

MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know - MSN

Ähnlich wie MAIA